|1.||Álvarez-Hernández, Diego Abelardo: 1 article (10/2015)|
|2.||Garza-Mayén, Gilda Sofía: 1 article (10/2015)|
|3.||Vázquez-López, Rosalno: 1 article (10/2015)|
|4.||Palmer, Tiffany: 1 article (08/2015)|
|5.||Gao, Ning: 1 article (08/2015)|
|6.||Doig, Peter: 1 article (08/2015)|
|7.||Mills, Scott D: 1 article (08/2015)|
|8.||Thresher, Jason: 1 article (08/2015)|
|9.||Andrews, Beth: 1 article (08/2015)|
|10.||Fan, Jun: 1 article (08/2015)|
|1.||Bacterial Infections (Bacterial Infection)
11/13/2014 - "Compound 3 is a potent aminobenzimidazole urea with broad-spectrum Gram-positive antibacterial activity resulting from dual inhibition of bacterial gyrase (GyrB) and topoisomerase IV (ParE), and it demonstrates efficacy in rodent models of bacterial infection. "
06/01/2010 - "The fluorinated quinolone, ciprofloxacin, is an antibiotic effective for treating bacterial infections by inhibiting the enzyme activity of the DNA type II topoisomerases DNA gyrase and topoisomerase IV. The genes that encode the subunits of DNA gyrase (gyrA and gyrB) and topo IV (par C and parE) contain hotspots within an area known as the quinolone resistance-determining region (QRDR). "
08/21/2015 - "We characterized the inhibition of Neisseria gonorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (AZD0914 will be henceforth known as ETX0914 (Entasis Therapeutics)), a novel spiropyrimidinetrione antibacterial compound that is currently in clinical trials for treatment of drug-resistant gonorrhea. "
04/01/2011 - "CF-derived strains tend to harbour mutations in the efflux pump regulator nfxB, while non-CF strains tend to bear mutations in the efflux regulator mexR or in parC, which encodes one of two subunits of DNA topoisomerase IV. We suggest that differences in resistance mechanisms between CF and non-CF strains result either from local adaptation to different sites of infection or from differences in mutational processes between different environments. "
01/01/2015 - "A sitafloxacin regimen is highly effective on Mycoplasma genitalium infections, including those caused by the mycoplasmas harboring mutant topoisomerase IV with a quinolone resistance-associated amino acid change in ParC. "
08/01/2012 - "These compounds simultaneously inhibit DNA gyrase and Topoisomerase IV at similar nanomolar concentrations, reducing the likelihood of the spontaneous occurrence of target-based mutations resulting in antibiotic resistance, an increasing threat in the treatment of serious infections."
02/01/2006 - "The presence of fluoroquinolone resistance-associated mutations within the quinolone resistance-determining region of DNA gyrase and topoisomerase IV was investigated genetically in clinical isolates of Proteus mirabilis recovered from patients with urinay tract infections. "
10/01/2015 - "They directly inhibit DNA replication by interacting with two enzymes; DNA gyrase and topoisomerase IV. They have been widely used for the treatment of several community and hospital acquired infections, in the food processing industry and in the agricultural field, making the increasing incidence of quinolone resistance a frequent problem associated with constant exposition to diverse microorganisms. "
|4.||Urinary Tract Infections (Urinary Tract Infection)
04/01/2001 - "Gemifloxacin is a fluoroquinolone antibacterial compound with enhanced affinity for bacterial topoisomerase IV and is being developed for the treatment of respiratory and urinary tract infections. "
06/01/2005 - "Resistance to fluoroquinolones in urinary tract infection (UTIs) caused by Escherichia coli is associated with multiple mutations, typically those that alter DNA gyrase and DNA topoisomerase IV and those that regulate AcrAB-TolC-mediated efflux. "
02/01/2001 - "These results suggest that the AP site-induced poisoning of Topo IV does not arrest replication fork progression."
10/16/1998 - "Wild-type and drug-resistant alleles of Topo IV are co-dominant, but we find that mutations in recA, seqA, or gyrB result in unconditional dominance of the sensitive allele, the characteristic of a poisoning mode of inhibition. "
|1.||DNA Topoisomerase IV (Topoisomerase IV)
|3.||DNA (Deoxyribonucleic Acid)
|10.||GTP-Binding Proteins (G-Protein)